Under construction – not a live service
Sign in

2024-515259-40-00RecruitingPhase 2/3

Contrast-enhanced ultrasound for sentinel node detection in patients with melanoma, breast cancer or head & neck cancer

Contrast-enhanced ultrasound for sentinel node detection in patients with melanoma, breast cancer or head & neck cancer (N24CUS)

Source: EU CTIS (euclinicaltrials.eu) · Last updated 9 Dec 2024 · Not updated for over 12 months - ask the site whether it is still open

Next steps

Brief summary (registry, in English)

To assess the sensitivity and specificity of CEUS for intra-operative SN localization compared to the gold standard (99mTc nanocolloid).

Status (registry)
Recruiting
Phase (registry)
Phase 2/3
Study type
Interventional
Enrollment
91 (estimated)
First submitted
9 Sept 2024
Start date
7 Jul 2025
Lead sponsor
Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting
Diseases
Melanoma
EU CT number
2024-515259-40-00

What you commit to

  • Study type: Interventional · Phase 2/3
  • Planned participants: 91
  • 1 site in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.

Who cannot take part

Copied verbatim from EU CTIS (euclinicaltrials.eu) and grouped by topic. Only the trial team decides who can take part.

Other illness

  • Any known clinically significant acute hypersensitivity reaction to the study medication, such as eggs or egg products
  • Other contra-indications for Sonazoid contrast agent, including arteriovenous cardiac or pulmonary shunt, serious coronary arterial disease and serious pulmonary disease

Other

  • Pregnancy

Who the study is looking for

  • Aged 18 years or older
  • Patient has been diagnosed with cancer in the skin (melanoma), breast or head & neck (including melanoma of head and neck area)
  • In case of a melanoma: it should be located in the limbs or head and neck area
  • Scheduled for a surgical SN procedure at the NKI-AvL
  • Patient provides written informed consent

Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers

Full criteria on EU CTIS (euclinicaltrials.eu)

Sites (1)

Sites in registry order. Save your city in your profile to sort them by distance.

SiteCityCountrySite status
Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis StichtingAmsterdamNetherlandsRecruiting

Are you the coordinator? Confirm the details

This page is information, not medical advice. Discuss any trial with your doctor.